ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight
January 25, 2019 7:10 AM ESTJPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.
Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More
Goldman Sachs Downgrades ResMed (RMD:AU) (RMD) to Neutral
January 25, 2019 7:01 AM ESTGoldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).
Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More
ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss
January 24, 2019 4:09 PM ESTResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $651.1 million versus the consensus estimate of $672.91 million.
Revenue increased 8% to $651.1 million; up 9% on a constant currency basisGross Margin expanded 70bps to... More